Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
Category: #health  By Pankaj Singh  Date: 2019-08-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
  • Outputs from single ascending dose specify that TERN-201 is well tolerated and generally safe & can inhibit plasma SSAO activity.
     
  • This trial has now transitioned onto the next level; multiple-ascending dose phase.

Terns Pharmaceuticals, Inc., an international biopharmaceutical company aimed at developing and discovering innovative therapies to treat cancer and non-alcoholic steatohepatitis (NASH), reportedly announced interim outputs of, currently under progress, clinical trial of TERN-201, an inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), being made for NASH treatment.

Interim data of first clinical study of TERN-201 tells that single, oral TERN-201 administrations were well handled with no important safety findings or any adverse events experienced that would lead to discontinuation. Every dose level studied showed reduction from baseline in SSAO activity of plasma that was maintained up to a week after the single dose TERN-201 administration. Study has now transitioned to multiple dose phase based on these outputs.

Chief Medical Officer of Terns, Erin Quirk, M.D. stated that the data seen till date from the clinical study in Phase 1 of TERN-201 has been encouraging and showed that TERN-201 is capable of being a therapy to treat liver fibrosis and NASH. Terns has further advanced two compounds into clinical development this year with TERN-101, a FXR agonist, and Tern-201 in current studies.

Quirk added that the company looks forward to check further outcomes from Phase 1 studies of TERN-201 and TERN-101 in this year as the company progresses towards its goal of unveiling effective and safe combination treatments for NASH.

Initially, TERN-201 was developed and discovered by Eli Lilly & Company. Terns made a global exclusive deal with Eli Lilly last year to manufacture, develop and commercialize TERN-201 for treating NASH. In Vienna, at International Liver CongressTM 2019, Terns presented preclinical information expressing that TERN-201 enhances NAFLD Activity Score (NAS) & fibrosis in rodent subjects of NASH.

 

Credit Source:

https://www.ternspharma.com/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...

Databricks buys 8080 Labs to boost its low code/no code offerings
Databricks buys 8080 Labs to boost its low code/no code offerings
By Pankaj Singh

California-based enterprise software company- Databricks has acquired German software startup 8080 Labs that developed bamboolib- a leading GUI for the Python-based Pandas data analysis and manipulation system. The purchase of 8080 Labs makes the fi...

Google rolls out GNI Advertising Lab for news publishers in India
Google rolls out GNI Advertising Lab for news publishers in India
By Pankaj Singh

American tech giant, Google LLC has recently announced the launch of Google News Initiative (GNI) Advertising Lab program for supporting small and medium-sized news publishers that generate original and accurate news for regional and local communitie...